Non-invasive tests in gastric diseases

Mario, F. Di; Cavallaro, L.G.

doi:10.1016/j.dld.2008.02.028

Cited by 91 publications

(75 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From the literature it can be concluded that ghrelin levels in the gastric mucosa significantly decrease with more advanced histopathological changes, especially after the atrophic gastritis stage [34,35] . It has been suggested that the level of this hormone can be considered as one of the markers of gastric mucosal change progression and, at the same time, can be one of the indications for gastroscopy.…”

Section: Discussionmentioning

confidence: 99%

Gastric ghrelin in relation to gender, stomach topographyand Helicobacter pylori in dyspeptic patients

Stec−Michalska¹,

Malicki²,

Michalski³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To investigate the level of gastric ghrelin in stomach mucosa of dyspeptic patients in relation to Helicobacter pylori (H pylori ) infection, bacterial cytotoxicity, topography and gender. METHODS:The study comprised 40 premenopausal women (19 H pylori positive) and 48 men (17 H pylori positive) with functional dyspepsia. All gastric biopsy specimens revealed normal mucosa or non-atrophic gastritis. Gastric ghrelin concentration was determined by Enzyme linked immunosorbent assay. The cagA and vacA strains of bacterial DNA were identified by multiplex polymerase chain reaction. RESULTS:In general, infection with H pylori caused an increase in gastric ghrelin level regardless of gender and stomach topography. Significantly more hormone was present in both, non-infected and H pylori positive female samples, as compared to males. The distribution of bacterial strains showed cagA (+) vacA s1m1 and cagA (-) vacA s2m2 genotypes as the most common infections in the studied population. A tendency to higher ghrelin levels was observed in less cytotoxic (cagA negative) strain-containing specimens from the antrum and corpus of both gender groups (without statistical significance). CONCLUSION: An increase in gastric ghrelin levelsat the stage of non-atrophic gastritis in H pylori positive patients, especially in those infected with cagA (-) strains, can exert a gastroprotective effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastric ghrelin in relation to gender, stomach topographyand Helicobacter pylori in dyspeptic patients

Stec−Michalska¹,

Malicki²,

Michalski³

et al. 2009

WJG

View full text Add to dashboard Cite

show abstract

“…The GastroPanel, used to detect gastric mucosa variations including atrophic gastritis, incorporates the biomarkers serum pepsinogen I (PGA1) and serum pepsinogen II (PGA2), gastrin-17 as well as antibodies against Helicobacter pylori. Because most stomach cancers arise from chronic inflammations such as gastritis (102), GastroPanel may aid in the early-stage diagnosis of the cancer or may also aid in the identification of individuals who may be at increased risk of developing stomach cancer once inflammation of their gastric mucosal wall has been confirmed.…”

Section: Stomach Cancermentioning

confidence: 99%

Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review

Zaenker

Ziman

2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

135

111

View full text Add to dashboard Cite

Current diagnostic techniques used for the early detection of cancers are successful but subject to detection bias. A recent focus lies in the development of more accurate diagnostic tools. An increase in serologic autoantibody levels has been shown to precede the development of cancer disease symptoms. Therefore, autoantibody levels in patient blood serum have been proposed as diagnostic biomarkers for early-stage diagnosis of cancers. Their clinical application has, however, been hindered by low sensitivity, specificity, and low predictive value scores. These scores have been shown to improve when panels of multiple diagnostic autoantibody biomarkers are used. A five-marker biomarker panel has been shown to increase the sensitivity of prostate cancer diagnosis to 95% as compared with 12.2% for prostate-specific antigen alone. New potential biomarker panels were also discovered for lung, colon, and stomach cancer diagnosis with sensitivity of 76%, 65.4%, and 50.8%, respectively. Studies in breast and liver cancer, however, seem to favor single markers, namely a-2-HS-glycoprotein and des-g-carboxyprothrombin with sensitivities of 79% and 89% for the early detection of the cancers. The aim of this review is to discuss the relevance of autoantibodies in cancer diagnosis and to outline the current methodologies used in the detection of autoantibodies. The review concludes with a discussion of the autoantibodies currently used in the diagnosis of cancers of the prostate, breast, lung, colon, stomach, and liver. A discussion of the potential future use of autoantibodies as diagnostic cancer biomarkers is also included in this review. Cancer Epidemiol Biomarkers Prev; 22(12); 2161-81. Ó2013 AACR.

show abstract

“…In clinical practice, there is no reliable biomarker for diagnosing gastric cancer. Most of the biomarkers of interest (for example, pepsinogens I and II, gastrin-17, interleukin-8, antibodies against H. pylori, CagA and parietal cells, and ghrelin) tend to be associated with atrophic or inflammatory conditions of gastric mucosa, but not specific to gastric cancer (di Mario and Cavallaro, 2008). Novel methods such as serum proteomic fingerprinting (Poon et al, 2006) and circulating miRNA profiling (Tsujiura et al, 2010) have been suggested as useful tools for noninvasive diagnosis of gastric cancer.…”

Section: Dysregulated Mirnas In Gastric Cancermentioning

confidence: 99%